Fig. 3: Duration of treatment and best percentage change from baseline in target lesions in patients with EOC. | British Journal of Cancer

Fig. 3: Duration of treatment and best percentage change from baseline in target lesions in patients with EOC.

From: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

Fig. 3

a Duration of treatment. b Best percentage change from baseline in target lesions. Symbols > in (a) and + in (b) denote the seven patients who continued pamiparib after closure of the study. BID twice a day, BRCA breast cancer susceptibility gene, CR complete response, EOC epithelial ovarian cancer, HRD homologous recombination deficiency, MU mutated, NA not applicable, NE not estimable, PD progressive disease, PR partial response, QD once a day, SD stable disease, UN unknown, WT wild-type.

Back to article page